(0.08%) 5 473.43 points
(0.10%) 39 152 points
(0.39%) 17 787 points
(0.07%) $80.89
(-3.66%) $2.66
(-0.79%) $2 312.30
(0.16%) $28.92
(3.52%) $1 021.10
(0.27%) $0.936
(0.70%) $10.68
(0.44%) $0.792
(-0.27%) $87.25
Live Chart Being Loaded With Signals
Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; and NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under Phase I/II clinical trial...
Stats | |
---|---|
今日成交量 | 99 416 |
平均成交量 | 472 941 |
市值 | 5.09B |
EPS | $-0.690 ( Q1 | 2024-05-09 ) |
下一个收益日期 | ( $-0.760 ) 2024-08-08 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-32.58 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.110 (0.14%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-06-14 | Conley Emily | Sell | 5 000 | Stock Option (Right to Buy) |
2024-06-14 | Conley Emily | Buy | 5 000 | Class A Common Stock |
2024-06-14 | Conley Emily | Sell | 4 777 | Class A Common Stock |
2024-06-14 | Conley Emily | Sell | 223 | Class A Common Stock |
2024-06-12 | Flynn James E | Buy | 3 789 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
-80.71 |
Last 100 transactions |
Buy: 133 880 | Sell: 1 327 400 |
音量 相关性
Nuvalent, Inc. 相关性 - 货币/商品
Nuvalent, Inc. 财务报表
Annual | 2023 |
营收: | $0 |
毛利润: | $0 (0.00 %) |
EPS: | $-2.17 |
FY | 2023 |
营收: | $0 |
毛利润: | $0 (0.00 %) |
EPS: | $-2.17 |
FY | 2022 |
营收: | $0 |
毛利润: | $0 (0.00 %) |
EPS: | $-1.480 |
FY | 2021 |
营收: | $0.00 |
毛利润: | $0.00 (0.00 %) |
EPS: | $-2.87 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Nuvalent, Inc.
Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; and NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under Phase I/II clinical trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。